Maxim Biomedical, Inc.
Biotechnology ResearchMaryland, United States11-50 Employees
Maxim Biomedical, Inc. is a biotechnology research company based in Rockville, Maryland. It collaborates with diagnostics and life science organizations to develop and manufacture scalable immunoassay formats, including lateral flow tests and ELISA platforms, guiding products from early feasibility through full-scale production. Drawing on more than 20 years of immunoassay development experience, the company emphasizes designs that support manufacturability and regulatory readiness to reduce downstream risk and shorten time to market for both emerging innovators and established diagnostics developers. Operating as a small to mid-sized, U.S.-based firm in the biotechnology research sector, Maxim Biomedical provides comprehensive development and manufacturing support across lateral flow, ELISA, and custom diagnostic platforms. It runs a vertically integrated manufacturing operation with capacity to produce over 15 million devices per month, enabling rapid iteration and reliable supply. The company maintains quality systems including FDA cGMP registration for medical device manufacture and distribution, 21 CFR Part 820 compliance, and ISO 13485:2016 certification, and it has documented a >99.99% acceptance rate for tests developed under U.S. government COVID response programs. In July 2024, the firm named Jonathan Maa as chief executive officer.